When LGG patients were classified into three groups (IDH1 wild-type, IDH1 mutations with 1p19q codeletion and IDH1 mutations without 1p19q codeletion) according to the guideline of the 2016 WHO classification of CNS tumors, the expression levels of PSAT1 were highest in the LGG group with IDH1 mutations but not chromosome 1p19q codeletion. This evidence concerns the gene IDH1 and central nervous system neoplasm.